Cochrane · systematic review · CD010052
Time course for blood pressure lowering of dihydropyridine calcium channel blockers
Ghamami, N, Chiang, SHY, Dormuth, C, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
HypertensionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
2
current version
GRADE rated
2
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Dihydropyridine calcium channel blockers compared with placebo for hypertension
Population: adults with primary hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Variation in the decrease in 24‐hour ambulatory hourly systolic blood pressure at 3‐12 weeks Dihydropyridine calcium channel blockers vs placebo | no estimate extracted | 16 studies · 2768 participants | Moderate Downgraded: risk of bias, inconsistency |
Variation in the decrease in 24‐hour ambulatory hourly diastolic blood pressure at 3‐12 weeks Dihydropyridine calcium channel blockers vs placebo | no estimate extracted | 16 studies · 2768 participants | Moderate Downgraded: risk of bias, inconsistency |